But even in the dominant pharmaceutical business, sales picked up more strongly again. However, Roche assumes that the demand for corona tests will decrease over the course of the year. At the same time, the drop in sales of important medicines due to competition from cheaper imitation drugs – so-called biosimilars – is likely to be less severe than in the previous year.
“Based on our current assessment of the development of the Covid-19 pandemic, we confirm the outlook for the full year,” said Roche CEO Severin Schwan. He expects sales to remain flat or grow by a low single-digit percentage in 2022. Earnings per non-voting equity security and bearer share adjusted for non-recurring items are expected to grow by a low to mid-percentage – also thanks to an increase in earnings from the shares repurchased by Novartis and then cancelled. The forecast applies to the exclusion of exchange rate fluctuations. The management promises the shareholders further increasing dividends.
Roche assumes that sales of corona tests and medicines will decrease by around two billion to around five billion francs (4.8 billion euros). Biosimilar sales will drop to around 2.5 billion. Francs estimated. Without these effects, the Group’s sales growth would be in the high single-digit percentage range. In the first quarter, the Group’s sales revenue increased by 11 percent to CHF 16.45 billion compared to the same period of the previous year. Roche thus performed in line with analysts’ expectations. The diagnostics division grew by 24 percent to CHF 5.29 billion. The pharmaceutical business increased by 6 percent to CHF 11.16 billion.
Roche only announces profit figures at the end of the first half of the year and at the end of the year.